Effect of uranyl nitrate-induced acute renal failure on the pharmacokinetics of sulfobromophthalein in rats
Tóm tắt
The effect of acute renal failure (ARF) on the pharmacokinetics of sulfobromophthalein (BSP) was investigated in order to elucidate if renal failure modifies the hepatic metabolism of drugs. ARF was induced by intravenous (iv) injection of uranyl nitrate (UN) to rats (5 mg/kg) five days before the experiment. Area under the plasma concentration-time curve (AUC) of BSP after portal vein (pv) injection increased by 2-fold and total body clearance (CL
t) decreased one half (p<0.01) in UN-induced ARF (UN-ARF) rats compared to the control rats. But the plasma disappearance of BSP afteriv injection did not differ significantly between control and UN-ARF rats. Since BSP is excretedvia the liver,CL
t representd the approximate hepatic clearance of BSP. Therefore, the decrease inCL
t represents a decrease in hepatic intrinsic clearance (CL
int) for BSP since plasma free fraction (f
p) of BSP was not affected by UN-ARF. The content of hepatic cytoplasmic Y-protein, which catalyzes BSP-glutathione conjugation and limits the transfer of BSP from blood to bile, increased significantly (p<0.01), however its binding activity (BA) for BSP was decreased significantly (p<0.01) by UN-ARF. The decrease inCL
int might have some correlation with the changed characteristics of hepatic Y-protein, specifically its decreased BA for BSP.
Từ khóa
Tài liệu tham khảo
Black, M., Biempica, L., Goldfischer, A., Grossman, S. and Arias, I.M.: Effect of chronic renal failure in rats on structure and function of the hepatic endoplasmic reticulum.Exp. Molec. Path. 27, 377 (1977).
Terner, U.K., Wiebe, L.I., Noujaim, A.A., Dossetor, J.B. and Sanders, E.: The effects of acute and chronic uremia in rats on their hepatic microsomal enzyme acivity.J. Clin. Biochem. 11, 156 (1978).
Leber, H.W.: Durg metabolism in uremia.Proc. Eur. Dial. Transplant. Ass. 13, 617 (1976).
Van Peer, A.P. and Belpaire, F.M.: Hepatic oxidative drug metabolism in rats with experimental renal failure.Arch. Int. Pharamacodyn. 228, 180 (1977).
Bowmer, C.J., Yates, M.S. and Emmerson, J.: The effect of acute renal failure on the pharmacokinetics of indocyanine green in the rat.Biochem. Pharmacol. 31, 2531 (1982).
Yates, M.S., Emmerson, J. and Bowmer, C.J.: Hepatic clearance of indocyanine green during the course of glycol-induced acute renal failure in the rat.J. Pharm. Pharmacol. 35, 335 (1983).
Yates, M.S., Emmerson, J. and Bowmer, C.J.: Pharmacokinetics of indocyanine green in rats with chronic renal failure.J. Pharm. Pharmacol. 35, 593 (1983).
Bowmer, C.J. and Yates, M.S.: Pharmacokinetics and biliary excretion of bromosulfophthalein,3H-ouabain and3H-taurocholic acid in rats with glycerol-induced acute renal failure.Br. J. Pharmacol. 75, 110 (1982).
Katayama, H., Fujiwara, J., Yasuhara, M., Okumura, K. and Hori, R.: Increased availbility of propranolol in rats with uranyl nitrate-induced acute renal failure.J. Pharm. Dyn. 7, 536 (1984).
Terao, N. and Shen, D.D.: Effect of experimental renal failure on the disposition kinetics ofl-propranolol in rats.J. Pharm. Exp. Ther. 227, 295 (1983).
Dundee, J.W. and Richard, R.K.: Effect of azotemia upon the action of intravenous barbiturate anesthesia.Anesthesiology 15, 333 (1954).
Elion, G.B.: Biochemistry and pharmacology of purine analogues.Fed. Proc. 26, 898 (1967).
Fillastre, J.P., Dubois, D. and Brunelle, P.:Modern Aspects in the Treatment of Arterial Hypertension. Boehringer Ingelheim, p. 81 (1973).
Leber, H.W., Harders, A. and Schutterle, G.: Untersuchungen zum Einfluss der Uramie und die Metabolisierung von Phenylbutazon und Aminophenazon beim Menschen.Klin. Wochenschr. 50, 1092 (1972).
Bennett, W.M., Singer, I., Golper, T.A., Feig, P. and Coggin, C.J.: Guidlines for drug therapy in renal failure. Ann. Intern. Med.86, 754 (1977).
Fabre, J., Freudenreich, J., Duckert, A., Pitton, J.S., Rudhardt, M. and Viricu, C.: Influence of renal insufifciency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline.Helv. Med. Acta. 33, 307 (1967).
Englert, E., Brown, H., Willardson, D.G., Wallach, S. and Simon, E.L.: Metabolism of free and conjugated 17-hydroxycorticosteroids in subjects with uremia.J. Clin. Endocr. 18, 36 (1958).
O’Brien, J.P. and Sharp, A.R.: The influence of renal disease on the insulin disappearanc curve in man.Metabolism. 16, 76 (1967).
Reidenberg, M.M., Kostenbauder, H. and Adams, W.: The rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients.Metabolism. 18, 209 (1969).
Ogg, C.S., Toseland, P.A. and Cameron, J.S.: Pulmonary tuberclosis in patients on hemodialysis.Br. Med. J. 11, 283 91968).
Rieder, J., Schwartz, D.E., Fernex, M., Bergan, T. Brodwall, E.K., Blumberg, A., Cottier, P. and Scheitlin, W.: Pharmacokinetics of the antibacterial combination sulfamethoxazole + trimethoprim in patients with normal and impaired kidney function.Antibiot. Chemother. 18, 148 (1974).
Myhre, E., Brodwall, E.K., Stenback, O. and Hansen, T.: Plasma turnover of α-methyldopa in advanced renal failure.Acta. Med. Scand. 191, 343 (1972).
Fabre, J. and Ohr, J.: Drug selection and dosage in renal insufficiency.Ergebn. Inn. Med. Kinderheik. 34, 45 (1974).
Maddoks, J.L.: Increased drug metabolism in chronic renal failure.Proc. Eur. Dial. Transplant. Ass. 13, 624 (1976).
Letteri, J.M., Melk, H., Louis, S., Kutt, H., Durante, P. and Glazko, A.: Diphenyldantoin metabolism in uremia.New Engl. J. Med. 285, 648 (1971).
Reidenberg, M.M., Lowenthal, D.T., Briggs, W. and Ggasparo, M.: Phenobarbital elimination in patients with poor renal function.Clin. Pharmacol. Ther. 20, 67 (1976).
Rasmussen, K., Jervell, J., Storstein, V. and Gjerdrum, K.: Digitoxin kinetics in patients with impaired renal function.Clin. Pharmacol. Ther. 13, 6 (1972).
Storstein, L.: Studies on digitalis II. The influence of impaired renal function on the renal excretion of digitoxin and its cardioactive metabolites.Clin. Pharmacol. Ther. 16, 25 (1974).
Held, H. and Enderle, C.: Elimination and serum protein binding of phenylbutazone in patients with renal insufficiency.Clin. Nephrol. 6, 388 (1976).
Maddocks, J.L., Wake, C.J. and Harber, M.J.: The plasma half-life of antipyrine in chronic uremic and normal subjects.Br. J. Clin. Pharmacol. 2, 339 (1975).
Reidenberg, M.M.: Drug metabolism in uremia.Clin. Nephrol. 4, 83 (1975).
Baker, K.J. and Bradley, S.E.: Binding of sulfobromophthalein sodium by plasma albumin. Its role in hepatic BSP excretion.J. Clin. Invest. 45, 281 (1966).
Habig, W.H., Pabst, M.J., Fleschner, G., Gatmaitan, Z., Arias, I.M. and Jakoby, W.B.: The identity of glutathione S-transferase B with ligandin, a major binding protein of liver.Proc. Nat. Acad. Sci. USA 71, 3879 (1974).
Javitt, N.B.: Wheeler, H.O., Baker, K.J., Ramos, O.L. and Bradley, S.E.: The intrahepatic conjugation of sulfobromophthalein and glutathione in the dog.J. Clin. Invest. 39, 1570 (1960).
Grodsky, G.M., Carbone, J.V. and Fanska, R.: Biosynthesis of a sulfobromophthalein mercaptide with glutathione.Proc. Soc. Exp. Biol. Med. 106, 526 (1961).
Meltzer, J.I., Wheeler, H.O. and Cranston, W.I.: Metabolism of sulfobromophthalein sodium in dog and man.Proc. Soc. Exp. Biol. Med. 100, 174 (1959).
Combes, B.: The biliary excretion of sulfobromophthalein sodium in the rat as a conjugate of glycine acid.J. Clin. Invest. 38, 1426 (1959).
Combes, B. and Stakelulm, G.S.: Conjugation of sulfobromophthalein sodium with glutathione in thioether linkage by the rat.J. Clin. Invest. 39, 1214 (1960).
Yokota, M., Iga, T., Sugiyama, Y., Suyama, A., Awazu, S. and Hanano, M.: Comjugative hepatic transport of sulfobromophthalein and its glutathione conjugate in rats.J. Pharm. Dyn. 4, 287 (1981).
Carone, F.A. and Spector, W.G.: The suppression of experimental proteinuria in the rat by compounds that inhibit increased capillary permeability.J. Pathol. Bacteriol. 80, 55 (1960).
Blantz, R.C. and Konnen, K.: The mechanism of acute renal failure after uranyl nitrate.J. Clin. Invest. 55, 621 (1975).
Fawcett, J.K. and Scott, J.: A rapid and precise method for the determination of urea.Eur. J. Clin. Pathol. 13, 156 (1960).
Searcy, R.L. and Cox, F.M.: A modified technique for ultramicro estimations of urea nitrogen.Clin. Chim. Acta. 8, 810 (1963).
Reitman, S. and Frankel, S.: A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases.Am. J. Clin. Pathol. 28, 56 (1957).
Levi, A.J., Gatmaitan, Z. and Arias, I.M.: Two hepatic cytoplasmic proteins, Y and Z, and their possible role in the hepatic uptake of bilirubin, sulfobromophthalein, and other anions.J. Clin. Invest. 48, 2156 (1969).
Gibaldi, M. and Perrier, D.Pharmacokinetics, vol. 1, Marcel Dekker: New York, Chapter 1, 2, 5, and Appendix 4 (1975).
Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T.: A pharmacokinetic analysis program (MULTI) for microcomputer.J. Pharm. Dyn. 4, 879 (1971).
Pang, K.S. and Rowland, M.: Hepatic clearance of drug I. Theoretical considerations of a well-stirred model and a pararell-tube model, influence of hepatic blood flow, plasma and blood cell binding, and hepatocellular enzymatic activity on hepatic drug clearance.J. Pharmacokinet. Biopharm. 5, 625 (1977).
Iga, T., Sugiyama, Y., Yokota, M., Tomono, Y., Awazu, S. and Hanano, M.: BSP transport in chronically CCl4-intoxicated rats.Biochem. Pharmacol. 26, 1867 (1977).
Takahashi, K., Wada, T., Higashi, Y. and Yata, N.: Pharmacokinetics in hepatic transport of amranth in rats introxicated with CCl4 and: anaphthylisothiocyanate.Chem. Pharm. Bull. 33, 4973 (1985).
Knochel, J.P. and Seldin, D.W.:The kiney vol. 2; Brenner, B.M. and Rechtar, F.C., Eds.: W.B. Saunders & Co. Philadelphia, Chapter 34 (1976).
Wernze, H. and Spech, H.J.: Untersuchungen uber Speicherkapazitat und Transportmaximum der Leber für Bromosulfophthalein bei Chronischer Niereninsuffizienz.Kin. Wschr. 49, 1318 (1971).